Conference Information
Greetings from the Co-Chairs of 22nd LSACJ 2022
It has been a while since we entered the data-driven era. Keywords such as informatics, artificial intelligence (AI), and machine learning have come to be heard in various fields. They also play extremely important roles in the medical and pharmaceutical fields. In the clinical field, informatics plays an extremely important role, centering on the utilization of clinical diagnostic data. In drug discovery, the analysis of molecular behavior and intermolecular interactions using quantum chemistry and the search for drug candidates using virtual screening and molecular dynamics simulation are also widely used. Advances in these core technologies have led to the development of a diverse range of drug discovery modalities for next-generation medicine and drug discovery, not only research centered on experiments. In recent days, digital medicine has begun to appear in clinical sites. We believe that such rapid technological progress will surely lead to people’s health and society’s prosperity. The theme of ISL2022 is “From Basic to Clinical” and it focuses on bridging basic research and clinical research. We plan to actively discuss the latest research results and academic content, regardless of the research fields.
We look forward to your participation. See you online.
Dan Ohtan WANG Ph.D.
RIKEN Center for Biosystems Dynamics Research, Team leader
Yu-Shi Tian Ph.D.
Graduate School of Pharmaceutical Science, Osaka University, Assis. Prof.
Bin ZHOU Ph.D.
Learning Health Society Institute, Chief Scientist
Greetings from the President of LSACJ (2022)
The Life Science Association of Chinese in Japan (LSACJ) was established in 1995 as a multidisciplinary and comprehensive academic society focusing on life sciences by Chinese scientists and Chinese students in Japan with a history of 27 years. The association was founded in 1995 as the Kansai Region Chinese Students' Association for Molecular Biology, and later developed into the Kansai Chinese Life Sciences Association, which was renamed to the present Life Sciences Association for Chinese Residents in Japan in 2005 on the occasion of the 10th anniversary of the association. Since its foundation, the association has been committed to the spirit of openness, tolerance, friendship, unity, and endeavor to improve communication and cooperation among its members, and to pursue scientific and technological innovation. The Association is also committed to promoting exchanges and cooperation between China and Japan in the field of life sciences.
In LSACJ 2022, we will focus on the theme of "Bench to Bedside", and experts and researchers will be invited to share the latest cutting-edge research results from basic to clinical stages. We will also invite experts who are familiar with pharmaceutical policies in China and Japan to explain the regulations and application process of clinical research in China and Japan. It is hoped that this conference will promote the translation of basic research into clinical applications and provide a platform for communication and interaction between Chinese and Japanese colleagues in different research fields.
We sincerely hope that all of you will participate.
Biao MA, Research Scientist
President of LSACJ (2022-)
HPC- and AI-driven Drug Development Platform Division, RIKEN Center for Computational Science
